Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer
The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and a potential dosing advantage over a Takeda Pharmaceutical product recently approved in this indication.
With $5M, Phantom GI Plans to Develop Minimally Invasive Alternative Ostomy Surgery Device
Phantom GI, a Tel Aviv-based medical startup, is developing the PercStoma device, a minimally invasive alternative to traditional ostomy surgery. The device would target patients with bowel obstructions who might otherwise be considered ineligible for surgery.
Diagnosis Is Beside the Point
Some of the thorniest problems in medicine that AI can improve have nothing to do with diagnosis. They have to do with triage.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition.
Allswell Raises $7M to Grow LGBTQ+ Behavioral Health Platform
Allswell's seed round was led by Rethink Impact, and included participation from Magnify Ventures, Ulu Ventures and Hopelab Ventures, joining existing investors Techstars and Amboy Street Ventures.